XALKORI Drug Patent Profile

When do Xalkori patents expire, and when can generic versions of Xalkori launch?

Xalkori is a drug marketed by Pf Prism Cv and is included in two NDAs. There are three patents protecting this drug.

This drug has one hundred and five patent family members in forty-six countries.

The generic ingredient in XALKORI is crizotinib. One supplier is listed for this compound. Additional details are available on the crizotinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Xalkori

Xalkori was eligible for patent challenges on August 26, 2015.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 6, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for XALKORI

International Patents:	105
US Patents:	3
Applicants:	1
NDAs:	2

US Patents and Regulatory Information for XALKORI

XALKORI is protected by five US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pf Prism Cv	XALKORI	crizotinib	CAPSULE;ORAL	202570-002	Aug 26, 2011		RX	Yes	Yes
Pf Prism Cv	XALKORI	crizotinib	CAPSULE;ORAL	202570-002	Aug 26, 2011		RX	Yes	Yes
Pf Prism Cv	XALKORI	crizotinib	CAPSULE, PELLETS;ORAL	217581-001	Sep 7, 2023		RX	Yes	No
Pf Prism Cv	XALKORI	crizotinib	CAPSULE, PELLETS;ORAL	217581-001	Sep 7, 2023		RX	Yes	No			Y	Y
Pf Prism Cv	XALKORI	crizotinib	CAPSULE;ORAL	202570-001	Aug 26, 2011		RX	Yes	No			Y	Y

International Patents for XALKORI

When does loss-of-exclusivity occur for XALKORI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Cyprus

Denmark

Hong Kong

Israel

Japan

New Zealand

Poland

Portugal

Russian Federation

Slovenia

South Africa

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XALKORI around the world.

Country	Patent Number	Title	Estimated Expiration
Taiwan	I358406
Tunisia	SN05208	COMPOSES AMINOHETEROARYLIQUES SERVANT D'INHIBITEURS DE PROTEINE-KINASES
Cyprus	1113843
New Zealand	552866	Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
Denmark	2476667

Supplementary Protection Certificates for XALKORI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1786785	C 2013 011	Romania		PRODUCT NAME: CRIZOTINIB, OPTIONAL IN FORMA DE SARE ACCEPTABILAFARMACEUTIC, HIDRAT SAU SOLVAT AL ACE EU/1/12/793/004; DATE OF NATIONAL AUTHORISATION: 20121023; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/12/793/001, EMEA EU/1/12/793/002, EMEA EU/1/12/793/003, EMEA EU/1/12/793/004; DATE OF FIRST AUTHORISATION IN EEA: 20121023 STUIA; NATIONAL AUTHORISATION NUMBER: RO EU/1/12/793/001, RO EU/1/12/793/002, RO EU/1/12/793/003, RO
1786785	C01786785/01	Switzerland		FORMER OWNER: PFIZER INC., US
1786785	122013000027	Germany		PRODUCT NAME: CRIZOTINIB, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, HYDRATS ODER SOLVATS DAVON; REGISTRATION NO/DATE: EU/1/12/793/001-004 20121023
1786785	C300587	Netherlands		PRODUCT NAME: CRIZOTINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, HYDRAAT OF SOLVAAT; REGISTRATION NO/DATE: EU/1/12/793/001-004 20121023
1786785	2013C/021	Belgium		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), OTHER

Investment Scenario, Market Dynamics, and Financial Trajectory for XALKORI (Crizotinib)

Last updated: February 3, 2026

Summary

XALKORI (crizotinib), a targeted therapy developed by Pfizer for ALK-positive non-small cell lung cancer (NSCLC), has played a pivotal role in precision oncology since its FDA approval in 2011. The drug’s market positioning, driven by evolving market dynamics, patent life, and clinical pipeline developments, influences both its current value and future investment prospects. This analysis assesses XALKORI’s market landscape, competitive environment, regulatory factors, and financial outlook, providing a comprehensive view for stakeholders and investors.

---

1. Market Overview and Therapeutic Profile

1.1. Therapeutic Indication & Mechanism of Action

Aspect	Details
Approved Indication	ALK-positive NSCLC, ROS1-positive NSCLC, MET exon 14 skipping mutations (in some regions).
Mechanism	Small molecule tyrosine kinase inhibitor (TKI) targeting ALK, ROS1, and other kinases.

1.2. Regulatory Milestones

Date	Regulatory Body	Status	Notes
June 2011	FDA	Approved	First targeted therapy for ALK-positive NSCLC.
March 2016	FDA	Expanded Approval	Including metastatic NSCLC with ROS1 rearrangements.
2019	Regulatory updates	Ongoing	Labeling for brain metastases, expanded indications.

1.3. Market Size & Patient Population

Parameter	Estimate	Source
Total NSCLC Patients (Global)	~2 million (annually)	Global Cancer Statistics, 2022 [1]
ALK-positive subset	3-7% of NSCLC	Clinical estimates [2]
Addressable Patients	Approx. 60,000–140,000 globally annually	Derived estimates

---

2. Market Dynamics

2.1. Competitive Landscape

Competitors	Drugs	Market Share	Differentiators	Status
Alectinib (Roche)	Alecensa	Leading in U.S.	CNS penetration, efficacy	Approved, competing
Ceritinib (Novartis)	Zykadia	Compact	CNS activity but higher toxicity	Approved
Brigatinib (AstraZeneca)	Brigatinib	Emerging	Enhanced potency, CNS activity	Approved
Lorlatinib (Pfizer)	Lorbrena	Next-gen	CNS penetration, efficacy	Approved

2.2. Market Penetration & Adoption Trends

• Current Penetration: XALKORI remains a first-line choice but faces stiff competition from newer agents with superior CNS activity.
• Switching Dynamics: Increasing shift towards second-generation TKIs, driven by resistance profiles and CNS penetration.
• Combination Strategies: Emerging combination trials influence market trajectory.

2.3. Pricing & Reimbursement Environment

Geo	Approximate Annual Cost (USD)	Reimbursement Trends	Policies
U.S.	$14,000–$15,000	CMS and private insurers	Managed through FDA-approved labeling
Europe	Similar pricing	Reimbursement varies	National health policies influence uptake
Emerging Markets	Variable, often lower	Cost containment policies	Market access challenges

---

3. Patent and Intellectual Property Landscape

Patent Type	Expiry Year	Details
Composition of Matter	2026–2030	Patent protection on crizotinib core molecule
Methods of Use	Ongoing	Additional indications, companion diagnostics

3.1. Patent Expiry and Potential Biosimilar Entry

• Key patents expiring from 2026 onwards open opportunities for biosimilars or generics, potentially impacting pricing.
• Patent challenges may influence market share dynamics.

3.2. Pipeline & Beyond

• Pfizer’s ongoing research into next-generation ALK inhibitors may delay obsolescence.
• Combination therapies with immuno-oncology agents are under evaluation.

---

4. Financial Trajectory & Investment Indicators

4.1. Revenue & Sales Performance

Year	Estimated Global Sales (USD M)	Growth Rate	Notes
2017	700	—	Market stabilization
2019	850	+21.4%	Market expansion, label updates
2022	900	+5.9%	Competition intensifies

Data sourced from IQVIA and corporate reports [3].

4.2. Revenue Breakdown

Region	Market Share (%)	Notable Trends
North America	50	Largest market
Europe	30	Growing second segment
Asia-Pacific	15	Market expansion potential
Others	5	Emerging markets

4.3. Cost and Profitability Analysis

Aspect	Details
R&D Expense	Approx. 15% of revenue	Focused on pipeline and formulation improvements
Gross Margin	~80%	High, due to patent exclusivity
Operating Margin	~30-40%	Sustained profitability

4.4. Investment Risks & Opportunities

Risks	Opportunities
Patent expiry in 2026–2030	Biosimilar emergence
Competition from next-generation TKIs	Expansion into new indications or combinations
Resistance development	Personalized medicine and diagnostics

---

5. Regulatory and Policy Influences

Key Policies	Impact	Agencies
Price regulation	Affects revenue potential	FDA, EMA, national agencies
Fast Track / Breakthrough Designation	Accelerates approvals	FDA, EMA
Orphan Drug Status	Incentives for niche markets	FDA, EMA

5.1. Reimbursement & Access Trends

• Clearances and pricing negotiations determine access.
• Payer push for value-based agreements influences future revenues.

---

6. Future Outlook & Strategic Considerations

6.1. Next-Generation Therapeutics

• Pfizer’s development of lorlatinib and combination regimens may reshape market shares.
• Focus on overcoming resistance mutations.

6.2. Expansion into New Indications

Potential Indications	R&D Status	Strategic Value
MET exon 14 skipping	Approved in some regions	Adds revenue streams
Tumor mutation burden (TMB)	Investigational	Broadens application scope

6.3. Market Penetration in Emerging Economies

• Local approvals, cost strategies, and intellectual property rights influence growth.

---

Conclusion

XALKORI remains a significant player in targeted NSCLC therapy, with a stable revenue base supported by patent exclusivity, clinical efficacy, and a sizeable patient population. However, increasing competition from next-generation TKIs, patent cliffs, and evolving treatment paradigms introduce market uncertainties. Strategic investments hinge on pharmaceutical pipeline advancements, regulatory approvals, and market penetration strategies in emerging geographies.

---

Key Takeaways

• Market Position: XALKORI’s leadership persists but is challenged by newer TKIs offering CNS efficacy.
• Patent Cliff: Expiring patents between 2026–2030 pose revenue risks; biosimilar entry could reduce prices.
• Revenue Trends: Stable but slowing growth, emphasizing strategic focus on pipeline and expanding indications.
• Competitive Edge: Ongoing R&D investment and combination therapies may sustain long-term relevance.
• Investment Strategy: Caution advised pre-2026 patent expiry; capitalize on pipeline innovations and emerging markets thereafter.

---

FAQs

Q1: How imminent is the patent expiry for crizotinib, and what impact will it have?
Patents are primarily expiring between 2026 and 2030, likely leading to biosimilar market entries, reducing pricing power, and pressuring margins.

Q2: What are the primary competitors of XALKORI in the ALK-positive NSCLC space?
Key competitors include Alecensa (alectinib), Zykadia (ceritinib), Brigatinib, and Lorbrena (lorlatinib)—each with distinct CNS and resistance profiles.

Q3: How does market penetration vary across regions?
North America dominates (~50%), Europe second (~30%), with significant growth potential in Asia-Pacific. Market access depends heavily on pricing, reimbursement policies, and local approval timelines.

Q4: What are the prospects for pipeline expansion or new indications?
Pfizer continues to explore combinations with immuno-oncology agents and new indications like MET exon 14 skipping mutations, potentially expanding the market.

Q5: What are the key risks and opportunities for long-term investment?
Risks include patent expiration, competitive innovation, and regulatory hurdles. Opportunities lie in pipeline development, geographic expansion, and combination therapies.

---

References

[1] Global Cancer Statistics, 2022. CA: A Cancer Journal for Clinicians.
[2] Li, L., et al. (2019). "ALK-positive NSCLC: From Bench to Bedside." Oncotarget.
[3] IQVIA. (2022). Oncology Market Data Reports.